These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 34169786)

  • 21. Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy.
    Russo E; Drovandi S; Salvidio G; Verzola D; Esposito P; Garibotto G; Viazzi F
    Nutr Metab Cardiovasc Dis; 2020 Nov; 30(12):2343-2350. PubMed ID: 32912790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Allopurinol on the Progression of Chronic Kidney Disease.
    Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; de Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW;
    N Engl J Med; 2020 Jun; 382(26):2504-2513. PubMed ID: 32579811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
    Doria A; Galecki AT; Spino C; Pop-Busui R; Cherney DZ; Lingvay I; Parsa A; Rossing P; Sigal RJ; Afkarian M; Aronson R; Caramori ML; Crandall JP; de Boer IH; Elliott TG; Goldfine AB; Haw JS; Hirsch IB; Karger AB; Maahs DM; McGill JB; Molitch ME; Perkins BA; Polsky S; Pragnell M; Robiner WN; Rosas SE; Senior P; Tuttle KR; Umpierrez GE; Wallia A; Weinstock RS; Wu C; Mauer M;
    N Engl J Med; 2020 Jun; 382(26):2493-2503. PubMed ID: 32579810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uric acid in CKD: has the jury come to the verdict?
    Bonino B; Leoncini G; Russo E; Pontremoli R; Viazzi F
    J Nephrol; 2020 Aug; 33(4):715-724. PubMed ID: 31933161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
    Personett HA; Barreto EF; McCullough KB; Dierkhising R; Leung N; Habermann TM
    Leuk Lymphoma; 2019 Sep; 60(9):2271-2277. PubMed ID: 31223041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
    Kang DH
    Contrib Nephrol; 2018; 192():48-55. PubMed ID: 29393109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
    Park JH; Rivière I; Gonen M; Wang X; Sénéchal B; Curran KJ; Sauter C; Wang Y; Santomasso B; Mead E; Roshal M; Maslak P; Davila M; Brentjens RJ; Sadelain M
    N Engl J Med; 2018 Feb; 378(5):449-459. PubMed ID: 29385376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample.
    Durani U; Shah ND; Go RS
    Oncologist; 2017 Dec; 22(12):1506-1509. PubMed ID: 28904174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup.
    Chawla LS; Bellomo R; Bihorac A; Goldstein SL; Siew ED; Bagshaw SM; Bittleman D; Cruz D; Endre Z; Fitzgerald RL; Forni L; Kane-Gill SL; Hoste E; Koyner J; Liu KD; Macedo E; Mehta R; Murray P; Nadim M; Ostermann M; Palevsky PM; Pannu N; Rosner M; Wald R; Zarbock A; Ronco C; Kellum JA;
    Nat Rev Nephrol; 2017 Apr; 13(4):241-257. PubMed ID: 28239173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS; Thompson S; Tangirala K; Eaddy MT
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Uric Acid Exhibits Inverse Relationship with Estimated Glomerular Filtration Rate.
    Koratala A; Singhania G; Alquadan KF; Shimada M; Johnson RJ; Ejaz AA
    Nephron; 2016; 134(4):231-237. PubMed ID: 27548821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of dialysis requirement on outcomes in tumor lysis syndrome.
    Garimella PS; Balakrishnan P; Ammakkanavar NR; Patel S; Patel A; Konstantinidis I; Annapureddy N; Nadkarni GN
    Nephrology (Carlton); 2017 Jan; 22(1):85-88. PubMed ID: 27119419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit: a systematic review.
    Villeneuve PM; Clark EG; Sikora L; Sood MM; Bagshaw SM
    Intensive Care Med; 2016 Feb; 42(2):137-46. PubMed ID: 26626062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uric acid and the prediction models of tumor lysis syndrome in AML.
    Ejaz AA; Pourafshar N; Mohandas R; Smallwood BA; Johnson RJ; Hsu JW
    PLoS One; 2015; 10(3):e0119497. PubMed ID: 25775138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
    Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
    Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002.
    Odden MC; Amadu AR; Smit E; Lo L; Peralta CA
    Am J Kidney Dis; 2014 Oct; 64(4):550-7. PubMed ID: 24906981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI.
    Wonnacott A; Meran S; Amphlett B; Talabani B; Phillips A
    Clin J Am Soc Nephrol; 2014 Jun; 9(6):1007-14. PubMed ID: 24677557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Six-month survival and quality of life of intensive care patients with acute kidney injury.
    Nisula S; Vaara ST; Kaukonen KM; Reinikainen M; Koivisto SP; Inkinen O; Poukkanen M; Tiainen P; Pettilä V; Korhonen AM;
    Crit Care; 2013 Oct; 17(5):R250. PubMed ID: 24148658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
    Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW
    Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.